Figure 3.

In Vivo Efficacy of SAHA and Reolysin Is Enhanced in a Human Xenograft Model of Head and Neck Cancer

Nude athymic female mice (n = 10 per group) bearing subcutaneous SCC-74A human xenograft tumors (treatment started at 150 mm³) were treated with DMSO, SAHA (50 mg/kg), Reolysin (Reo) (2 × 10⁸ PFU), or SAHA plus Reolysin combinatorial therapy. (A) Tumor volume growth was assessed over time for each mouse in every treatment group. **p < 0.01 (difference between combination-treated mice and all other treatment groups; left panel). Kaplan-Meir survival curves for mice bearing subcutaneous SCC-74A tumors treated with SAHA, reovirus (RV), or the indicated combination (the treatment schema is provided below the plot). *p ≤ 0.001 (combination treatment differences compared to each individual treatment group; right panel). All survival studies were performed in duplicate. (B) Representative H&E- and macrophage (CD68)-stained tumors at time of death when tumors reached ∼1,500 mm³ at a magnification of ×400. Red arrows highlight immune infiltrate.